The federal agency’s National Center for Injury Prevention and Control is looking for input on “individual stakeholder’s values and preferences related to pain and pain management options,” it said in an email last week.
“Through this opportunity, CDC is seeking stakeholders’ perspectives on and experiences with pain and pain management, including, but not limited to, the benefits and harms of opioid use,” it said. “CDC invites input specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments (e.g., exercise therapy or cognitive behavioral therapy).”
While the notice published in the Federal Register does not explicitly reference cannabis or kratom, numerous individuals have taken the opportunity to submit their feedback on the therapeutic benefits of the substances as alternatives to prescription opioids in their pain management.
More than 200 people talked about either “marijuana” or “cannabis,” about 70 discussed CBD and more than 1,000 discussed kratom, a lesser-known herb that has also shown promise as a pain reliever. There were a total of 3,682 comments submitted as of Monday afternoon.
“I suffer from rheumatoid arthritis and have had 15 skin cancer removals and didn’t receive pain meds for any of those surgeries! I wouldn’t have made it without cannabis,” an anonymous commenter said. ” I never have any side effects nor does it slow me down. It actually helps ease the pain which enables me to do more physical activities! It’s much safer than alcohol and I don’t understand why the U.S. hasn’t legalized other than politics!”
Another person with chronic pain from a compression fracture said, “I use cannabis to relieve nerve and muscle pain. Cannabis relieves my pain effectively and doesn’t cause me as much impairment as opioids and other medication I was prescribed for the injury.”
A 65-year-old person who said he suffers from multiple muscular and skeletal birth defects described negative side effects from the opioid-based painkillers he was prescribed and said that he’s since reduced his dosage after incorporating cannabis into his regimen.
“Upon having daily regular doses of marijuana I was able to substantially reduce the oxycodone dosage,” he said. “There was a period where I stopped using oxycodone completely. Now, I use marijuana daily in conjunction with low 2.5mg doses (20mg/day) oxycodone. I realized the pain control was due to the combination of marijuana and opiate as soon as I began using marijuana regularly.”
NORML Deputy Director Paul Armentano told Marijuana Moment that an “estimated one in ten Americans suffers from chronic pain conditions that are unresponsive to conventional pain treatments, such as NSAIDS and opioids.”
“Because of this unmet need, and because many conventional analgesics possess the risk of serious adverse side-effects, including overdose death, it is understandable that many patients are seeking alternative treatment regiments, such as cannabis,” he said. “It is notable that the US Centers for Disease Control is seeking personal feedback from these patients and is looking to learn from their experiences.”
“The CDC’s call for public comments is a unique opportunity for this agency to hear directly from these tens of thousands of patients who are therapeutically benefiting from cannabis, and in many cases, substituting it in place of more dangerous opioids,” he added. “Ideally, this feedback will help guide the agency in amending and evolving their public health and pain management guidelines to better recognize the important role that cannabis can play as a relatively safe and effective analgesic for many chronic pain sufferers.”
A recent meta-analysis found that, on average, pain patients who use cannabis reported a 64-75 percent reduction in opioid dosages.
Another study released in April found that marijuana can mitigate symptoms of opioid withdrawal.
Late last year, researchers determined that states with legal marijuana access experience decreases in opioid prescriptions, and a separate study released the previous month showed that daily marijuana consumption is associated with reduced opioid consumption among chronic pain patients.
CDC’s comment period on pain management has so far received nearly three times as many as a recent Drug Enforcement Administration notice on increasing marijuana manufacturing for research purposes.
Visit our online store. Classification Of Keflex Cephalexin. Australian Pharmacy Shop: 100% quality, low price, 24/7 support, fast delivery. Get here.
It’s received slightly fewer compared to when the U.S. Department of Agriculture (USDA) opened a comment period for proposed regulations on hemp last year. The period saw more than 4,600 people comments.
People interested in weighing in on the CDC’s pain management query can submit comments through 11:59 PM ET on Tuesday.